Type 2 diabetes.
Conditions
Interventions
Retagliptin Group:Retagliptin
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria for type 2 diabetes as defined by the World Health Organization (WHO); 2. Gender is not restricted; age >=18 years; 3. Patients who have been prescribed Rigoratine according to the drug's instructions and the doctor's judgment; 4. Voluntarily participate in this study and sign an informed consent form. 5. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must observe the informed consent process and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Hyperglycemia due to other diseases; 2. Clinically diagnosed with other types of diabetes, such as type 1 diabetes; 3. Allergic to the trial medication or any of its components; 4. Severe renal dysfunction (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m²); 5. Pregnant or breastfeeding women; 6. Any other patients deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of adverse drug reactions (ADRs) and serious adverse events and ADRs of special interest (hypoglycemia, pancreatitis, coronary heart disease, heart failure, stroke).; | — |
Secondary
| Measure | Time frame |
|---|---|
| glycated hemoglobin;fasting blood sugar;2 hour postprandial blood sugar;microalbumin/creatinine ratio (ACR);weight; | — |
Countries
China
Contacts
Public ContactJixiong Xu
The first affiliated hostipal of nanchang university
Outcome results
None listed